Evidence map›Paper›PMID 34424567›Full record

ArticleAnnals of neurology2021

Th1 - CD11c

Kimitoshi Kimura, Youwei Lin, Hiromi Yamaguchi, Wakiro Sato, Daiki Takewaki, Misako Minote, Yoshimitsu Doi, Tomoko Okamoto, Ryosuke Takahashi, Takayuki Kondo and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. CD11cNeurology(R) neuroimmunology & neuroinflammation · 2024
    Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kimitoshi KimuraDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0002-8359-2886
Youwei LinDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Hiromi YamaguchiDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Wakiro SatoDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Daiki TakewakiDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Misako MinoteDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Yoshimitsu DoiDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Tomoko OkamotoMultiple Sclerosis Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Ryosuke TakahashiDepartment of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki KondoDepartment of Neurology, Kansai Medical University Medical Center, Osaka, Japan.
Takashi YamamuraDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
National Multiple Sclerosis Society · USKansai Medical University · JPKyoto University · JPNational Center of Neurology and Psychiatry · JP

Funding

Japan Agency for Medical Research and Development JP19ek0109382Japan Society for the Promotion of Science JP18K15473Ministry of Health, Labour and Welfare H26-nanchito(nan)-ippan-074Ministry of Health, Labour and Welfare H29-nanchito(nan)-ippan-043National Center of Neurology and Psychiatry 1-5National Center of Neurology and Psychiatry 25-4National Center of Neurology and Psychiatry 28-5
6 · The paper itself

Abstract

objectiveAlthough plasmapheresis is a treatment option for patients with autoimmune neurological diseases, treatment response varies greatly among patients. The main objective of this study was to find out if biological/immune traits correlate with a beneficial response.

methodsWe thoroughly analyzed immune phenotypes in paired blood samples from a cohort of 31 patients with multiple sclerosis before and after plasmapheresis, in parallel with clinical evaluation of treatment response.

resultsThe frequency of IFN-γ

interpretationTaken together, we postulate that Th1 cell - CD11c

Indexed as

PlasmapheresisAdultAutoimmune DiseasesB-LymphocytesCytokinesDendritic CellsHumansMaleMiddle AgedMultiple SclerosisTh1 CellsCytokines

Identifiers

PMID34424567
PMCPMC9293420
OpenAlexW3195057751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.